Vertex Pharmaceuticals Incorporated (VRTX)
Jun 29 close; Powered by IEX
Revenue growth higher than the industry and sector averages
Company’s profitability is improving
Forward PEG ratio low relative to industry peers
Buy analyst rating
Forward P/E ratio high relative to industry peers
Forward P/B ratio high relative to industry peers
- VRTX quarterly revenue growth was 27.30%, higher than the industry and sector average revenue growth (4.07% and 7.51%, respectively). See VRTX revenue growth chart.
- VRTX profitability is improving. The YoY profit margin change was 17.16 percentage points. See VRTX profitability chart.
- VRTX PEG ratio (P/E adjusted for growth) is 1.57, which is low compared to its industry peers’ PEG ratios. See VRTX PEG chart.
- VRTX average analyst rating is Buy. See VRTX analyst rating chart.